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Abstract   
Background: Cellular based therapeutic approaches for cancer rely on careful consideration 
of finding the optimal cell to execute the cellular goal of cancer treatment. Cell lines and 
primary cell cultures have been used in some studies to compare the in vitro and in vivo 
efficacy of autologous vs allogeneic tumour cell vaccines. 
Methods: This study examines the effect of -irradiation on a range of tumor cell lines in 
conjunction with suicide gene therapy of cancer. To determine the efficacy of this modality, 
a series of in vitro and in vivo experiments were conducted using genetically modified and 
unmodified tumor cell lines.   
Results: Following co-culture of HSV-TK modified tumor cells and unmodified tumor cells 
both in vitro and in vivo we observed that the PA-STK ovarian tumor cells were sensitive to 
-irradiation, completely abolishing their ability to induce bystander killing of unmodified 
tumor cells. In contrast, TK-modified human and mouse mesothelioma cells were found to 
retain their in vitro and in vivo bystander killing effect after -irradiation. Morphological 
evidence was consistent with the death of PA-STK cells being by pyknosis after -irradiation. 
These results suggest that PA-STK cells are not suitable for clinical application of suicide 
gene therapy of cancer, as lethal -irradiation (100Gy) interferes with their bystander killing 
activity. However, the human mesothelioma cell line CRL-5830-TK retained its bystander 
killing potential after exposure to similarly lethal -irradiation (100Gy). CRL-5830 may 
therefore be a suitable vehicle for HSV-TK suicide gene therapy.   
Conclusions: This study highlights the diversity among tumor cell lines and the careful 
considerations needed to find the optimal tumor cell line for this type of suicide gene 
therapy of cancer. 
Key words: Tumor cell lines, -irradiation, Suicide gene therapy, anti-tumor immune 
response, cell death, Bystander killing effect, and cancer clinical trials. 
 
 
 
Introduction 
 The central objective in cancer therapy is to kill the malignant cells while causing little or 
preferably no collateral damage to healthy cells. Suicide gene therapy, as applied to the 
treatment of cancer, holds the potential to achieve just that [1,2]. An example is the 
insertion of the herpes simplex virus thymidine kinase (HSV-TK) gene into cancer cells which 
are consequently induced to “commit suicide” when in the presence of otherwise non-toxic 
doses of ganciclovir (GCV) [3,4].  This selective toxic effect of the purine analogue ganciclovir 
is because HSV-TK phosphorylates ganciclovir, converting it ultimately to ganciclovir-
triphosphate, a toxic compound when inserted into the DNA of these transfected cells [5-7].  
As with any other gene therapy strategy, and any anti-cancer treatment approach, its main 
limitation is the selective targeting and transduction of all tumor cells in vivo [8].  However, 
it may not be necessary to transduce every tumor cell in vivo to bring about a clinically-
meaningful anti-tumor effect [9-11]. Indeed, it has been demonstrated that two types of 
“bystander tumor cell killing” mechanisms are mediated by this approach:  a) a “direct” 
bystander effect, due to the transfer of ganciclovir triphosphate from HSV-TK-positive tumor 
cells into untransfected neighboring cells [12-14], b) a systemic immunologically-mediated 
bystander effect due to the in-vivo immune presentation of tumor-specific/associated 
antigens following the killing of HSV-TK –expressing cells [15,16].   
The genetically modified HSV-TK human ovarian cancer cell line, PA1-STK, has been used for 
the treatment of solid tumors (administered intraperitoneally in patients with ovarian 
cancer) [17]. The in vitro culture of these cells in the presence of ganciclovir provoked 
bystander killing, but with limited cytotoxic activity in vivo [18]. The rationale for this 
strategy was that PA-STK cells, injected in the vicinity of the patient’s tumor bulk, could 
make contact with, and seed themselves onto, the patient’s tumor cells in vivo and, after 
treatment with ganciclovir, could commit suicide and kill the patient’s tumor cells by a 
“direct” bystander mechanism (e.g. gap junction mediated transfer of the phosphorylated 
ganciclovir from the HSV-TK positive cells to the TK negative cells.  This direct cytotoxicity 
could then induce a more systemic immunological bystander tumor-killing effect [19-21].  
 Irradiation in conjunction with cancer gene therapy may have several potential benefits. As 
well as synergistic killing of tumor cells, it may enhance the bystander effect by releasing 
tumor antigens, stimulating a broad anti-tumor immune response [19-22]. However, it is 
important to establish that irradiated HSV-TK-containing cells are still able to induce direct 
bystander killing, without contributing to the live tumor burden.  This is a particularly 
important consideration when such treatment is considered for conditions of low tumor cell 
burden, but poor prognosis, such as surgically debulked advanced malignancies.  
The objective of the present studies was to assess the efficacy of bystander killing of 
unmodified tumour cells by HSV-TK modified cells, before and after irradiation.  The studies 
reported here show that -irradiation has a vastly different impact on the viability of tumor 
cells in vitro; some die within hours whereas others remain metabolically active for several 
days.  The consequences of such different sensitivities to -irradiation are that the highly 
radiosensitive cells failed to mediate efficient bystander killing either in vitro or in vivo, 
whilst the less radiosensitive cells were able to mediate efficient bystander killing both in 
vitro and in vivo. These studies highlight the importance of sensitivity to -irradiation for the 
development of allogeneic cell lines for the clinical application of HSV-TK mediated 
bystander killing of tumor cells.  
 Methods 
Cell lines 
Human mesothelioma cell lines, CRL-5915, 5820, and 5830 were obtained from the 
American type culture collection (Rockville, MD, USA) with the permission of Prof. A Gazdar 
(MD Anderson Cancer Center, Texas, USA)23. Mouse mesothelioma cell lines, ABI (H-2d) 
from BALB/c mice, AE17 (H-2k) from CBA mice, and AC29 (H-2b) from C57BL/6 mice were 
obtained from Prof. B. Robinson, QEII Medical Centre, University of Western Australia, 
Nedlands, Australia24. Human ovarian tumor (teratocarcinoma) cell line, PA-1 and PA-STK 
were obtained from Prof. S Freeman, Tulane University Medical School, New Orleans, USA 
[17]. Three ovarian tumor cell lines already available in the laboratory were: OVC-432 
(ovarian carcinoma, a kind gift from Dr C. Dohring, Basel Institute for Immunology, Basel, 
Switzerland25, SKOV-3 (ovarian adenocarcinoma) [26], and OIB, an ovarian tumor cell line 
established by Prof. F Farzaneh in the Molecular Medicine Department27. All human cell 
lines were maintained in DMEM, supplemented with 10% Fetal Calf Serum (FCS) and 1% 
sodium pyruvate. In the case of mouse mesothelioma cells, the RPMI-medium was 
supplemented with 5% FCS, 20mM HEPES, 50mM 2-mercaptoethanol (2ME) and 2mM 
glutamine.   
 
Retroviral infection  
Cells to be infected were seeded at a density of 5x105 cells per 10 cm plate, 24 hrs before 
infection. Virus producing cells were also grown to about 90% confluence, and the medium 
changed 10 hrs prior to harvest of the culture medium to ensure that fresh virus containing 
supernatant was used [28]. 
The medium from virus producing cells was removed and filtered through a 0.45m pore-
size filter to remove cell debris but allowing passage of the viral vector through the filter. To 
enhance the retroviral infection, 8g/ml of polybrene (Sigma Aldrich, Poole, UK) was added 
to the culture medium. Polybrene is required for coating of target cells in order to neutralise 
their negative surface charge, therefore increasing the efficiency of infection [29,30]. The 
medium from the cells to be infected was removed prior to infection, and the vector-
polybrene mixture added. After 10 hrs of infection the medium was changed. 48 hrs after 
infection, the medium was removed and replaced with fresh medium containing G418 at 
1mg/ml. G418 resistant clones were expanded. 
In vitro GCV-sensitivity studies on the tumor cell lines 
 
 The in vitro studies examining the effect of GCV on the HSV-TK expressing mesothelioma 
and ovarian carcinoma cells, as well as the untransduced cells, were performed in 96-well 
plates. Transduced and untransduced cells were plated in triplicate at two densities, 104 
cells/well and 105 cells/well for comparison. After 2 days, the medium was replaced by fresh 
DMEM containing the indicated concentrations of GCV in the range 10,000M to 0.01M. 
Cells were then incubated at 37 C in humidified 5 % CO2 for 5 days. Sensitivity to GCV 
treatment was measured by using a colorimetric cell proliferation assay that measures 
viable cell dehydrogenase activity, the microculture tetrazolium cell proliferation assay [31]. 
20l of 5 mg/ml MTT (Sigma Aldrich, Poole, UK) was added to each well for 3hrs and the 
cells in each well were solubilised in 150l of MTT solubilisation solution. After overnight 
incubation, the optical density of each well was measured on a 96-well plate reader 
(Dynatech, Reading, UK) set at 570nm wavelength. Known concentrations of cells were also 
plated, cultured in the presence of MTT, and similarly solubilized. The absorbance reading of 
these control cells represents the metabolic activity of a known number of cells and was 
used to generate a standard curve in Microsoft Excel. The absorbance reading for each 
sample (well) was directly compared with the standard curve, and the numbers of viable 
cells were determined accordingly.   
Bystander killing effect studies 
The bystander effect was determined by mixing HSV-TK expressing cells with untransfected 
cells at the indicated ratios. Cells were then plated in triplicate in 10 cm plates at two 
densities, 1x105 and 5x105 cell/ plate to ensure cell-cell contact and to compare the in vitro 
effect of cell densities on the bystander effect. Two days later, the cells were treated with 
50 M GCV and incubated at 37 C, 5% CO2 for 10-14 days. The plates were then stained 
with 2% methylene blue and stained cells were counted.  
In order to calculate the effect of GCV on the mixed PA-STK and PA-1 populations, the 
number of colonies counted were expressed as a percentage of the total number of colonies 
in the co-cultured TK+ve and TK-ve tumor cells at the indicated ratios of the two cell 
populations in the presence of the indicated concentrations of GCV. A graph was obtained 
by plotting the percentage of surviving colonies. 
-irradiation of HSV-TK modified tumor cells 
2x106 tumor cells resuspended in 5ml of DMEM were -irradiated (100Gy) using a Gamma 
cell-1000 (Atomic Energy of Canada Ltd. Source: 137Cs). 
Cytospin histological analysis  
A 100l aliquot of 104 cells/ml in PBS was used to prepare cytospin slides using a cytospin 
system (Hettich, Salford, UK), fixed in 10% formalin for 10 minutes, left overnight to air-dry 
and then stained by the Papanicolaou staining method [32,33]. 
 
 
Measurement of apoptosis and necrosis by FACS analysis 
Tumor cells were resuspended in 100l of working labelling solution and incubated for 
15min in the dark. Two control tubes were used: cells stained with Annexin V-FITC (Becton 
Dickinson, Oxford, UK) alone and cells stained with PI alone [34,35]. The cells were then 
analysed by flow cytometry using a FACScan analyser (Becton Dickinson, Oxford, UK).  
Cell cycle analysis  
Cells were irradiated at 100Gy and incubated overnight at 37C, in 5% CO2, resuspended in 
1ml of staining buffer (0.1% sodium citrate, 0.1% Triton-X100 and 10g/ml propidium iodide 
in dH2O), vortexed and left overnight at 4C in the dark. The cells were then analysed by 
flow cytometry using a FACScan analyser. 
 
In vivo studies: Inoculation, establishment and treatment of the tumors 
intraperitoneally (IP) in mice 
AB1 mouse mesothelioma adherent tumor cells were harvested by washing with versene 
only and re-suspended in 0.2 ml of PBS. Tumors were established IP in female BALB/c mice 
by injecting the mesothelioma cells (AB1 tumor cell line), at different doses (1x105, 5x105 
and 1x106/100ml PBS) using a 26-gauge needle, to establish the TD50 for the tumor cell line, 
according to Home Office regulations. Mice (n=45) were injected i.p. with AB1 tumor cells 
on day 0. Nine days later, animals were assigned to nine groups (n=5 per group). GCV 
treatment was started at day 10. GCV (Cymevene 500mg; Roche, Switzerland) was diluted 
in sterile DMEM to a stock concentration of 50mg/ml. The stock solution of GCV was diluted 
in DMEM to a concentration of 2mg/ml, and 1ml of the stock was injected IP once a day for 
five consecutive days. Mice were monitored every two days to palpate the tumor. At post-
mortem, all tumor nodules were counted and measured using a calliper (for each nodule, 2 
perpendicular diameters were recorded). Tumor volume was calculated for each nodule 
assuming spherical shape and the total tumor volume was calculated by adding all the 
calculated values for each mouse.  
 
Statistical analysis 
Statistical analysis was performed using the Microsoft Excel program. Differences between 
groups were analysed using Student’s paired t-test. A P value of < 0.05 was considered as 
significant.   
 
Results 
 
PA-STK cells irradiated at 100Gy lose their ability to induce bystander killing  
Irradiation of PA-STK cells (100Gy) substantially reduced their ability to induce bystander 
killing of unmodified PA-1 cells (Figure 1A). This study was carried out at the optimum 
number of 5x105 cells per 10 cm3 plate as previously determined (data not shown). A 
possibility was that the irradiation stopped the growth of PA-STK cells and therefore 
reduced the possibility of cell to cell contact in the tissue culture plate. This experiment was 
therefore repeated at a higher cell density of 2x106 cells/plate. Increasing the cell density 
did not restore the bystander effect (Figure 1B). At both cell densities, irradiated PA-STK 
cells were highly significantly less efficient at mediating the bystander effect at a 50:50 ratio 
than unirradiated cells (P = 0.04). Similar data were obtained in three further repeats of this 
experiment.   
-Irradiated (100Gy) human and mouse mesothelioma cells retain the ability to 
induce bystander killing. 
In contrast to the PA-STK cells, the mouse mesothelioma AE17-STK cells retain their capacity 
to induce bystander killing after -irradiation (100Gy, Figure 2A). Human mesothelioma cells 
CRL-5830-TK, were similarly able to retain their bystander killing activity after -irradiation 
(Figure 2B). In neither case was there a significant difference in efficacy between irradiated 
and unirradiated cells (P>0.45 at all cell ratios). 
 Investigation of PA-STK cell death after irradiation 
Microscopic examination of the irradiated (100Gy) PA-STK and PA-1 cells revealed that they 
were very sensitive to irradiation. The cells did not attach to the culture plate after 
irradiation, when visualised the next day (Figure 3).   In contrast, OVC-432 cells were able to 
efficiently adhere to the culture dish, even after 100Gy -irradiation.  These cells, in 
common with all other cell lines tested (OVC-432, SKOV-3, OIB, CRL-5830, CRL-5839-STK, 
CRL-5820, CRL-5915, AE17, AE-STK, AB-1, AC-29, HL-60) were able to attach efficiently to 
substrate and remain metabolically active for about 3 days before eventually losing surface 
adherence (data not shown).  
A dose range of irradiation from 1 to 100Gy was then tested on PA-STK cells. For this 
purpose the cells were trypsinised, -irradiated and then plated onto tissue culture plates. 
The next day it was observed that even the PA-STK cells irradiated at 1Gy had lost their 
ability to adhere to the tissue culture plates.  Further cell viability studies were performed 
using the MTT assay to determine their viability, showing that these cells were non-viable at 
all -irradiation doses. Moreover, these cells failed to mediate any in vitro bystander effect 
at all -irradiation doses tested (data not shown). 
 Analysis of cell death in PA-STK cells 
The first objective was to quantitatively record cell death during a time course study 
following -irradiation using the trypan blue dye exclusion method (Figure 4). The control 
cell line used in this experiment was another ovarian cancer cell line, OVC-432, as well as 
non-irradiated PA-STK cells. The vast majority (over 90%) of the irradiated PA-STK cells died 
by 18 hours post irradiation. However, this was not the case for control cells which survived 
beyond 48 hours.  
Additionally, Annexin-V and propidium iodide staining of cells was used as a method to 
quantify the proportion of apoptotic and necrotic cells in the -irradiated population of PA-
STK cells, respectively. In this experiment HL-60 cells treated with staurosporin (1mg/ml for 
4 hours) were used as positive control cells34,35. As shown in Fig. 5, only a small proportion 
of PA-STK cells were dying by apoptosis. In order to further examine the mechanism of cell 
death in the irradiated PA-STK cells, cytospin preparations were examined 18 hours later. 
The non-irradiated PA-STK cells served as controls. The cytospin histological analysis of the 
irradiated PA-STK cells suggests that these cells die by pyknosis, a form of necrosis (Figure 
6). Pyknosis is characterised by nuclear shrinkage and increased basophilia36. In the 
irradiated PA-STK cells the DNA condensed into a solid, shrunken basophilic mass. The only 
clear inference which can be drawn from these data is that the radiation induced death in 
the vast majority of PA-STK cells is due to necrosis/pyknosis, rather than apoptosis.  
 
In vivo bystander killing activity   
To establish an allogeneic TK-tumor cell/GCV treatment model, a series of experiments were 
conducted to repeat and extend previous in vivo studies. The treatment groups in Figure 6 
were used to assess and compare the activity of PA-STK cells (irradiated and non-irradiated) 
as a possible vehicle for HSV-TK suicide gene therapy with other TK expressing tumor cells. 
In this experiment BALB/c mice were injected with the syngeneic murine AB1 mesothelioma 
cells intraperitoneally (1 x106 cells per mouse) on day 0 (to act as the experimental groups), 
and one group of mice acted as healthy controls. Nine days later, the mice were separated 
into 9 different treatment groups. Group 1: PBS alone intraperitoneally (2 ml), Group 2: 
AE17-STK alone (2 ml containing 1 x106 cells), group 3: GCV alone (2 mg/ml/mouse for five 
consecutive days), Group 4: GCV + AE17-STK (GCV 2 mg/mouse for five consecutive days), 
Group 5: -irradiated AE17-STK/GCV (100Gy) + GCV, Group 6: unirradiated PA-STK cells + 
GCV, Group 7: -Irradiated PA-STK (100Gy) + GCV, Group 8: CRL5830-STK/GCV, and Group 9: 
-Irradiated CRL5830-STK/GCV (100Gy) . Co-cultured cells for treatment were used at 50% 
HSVTK modified tumor cells: 50% unmodified tumor cells. The mice were then left and 
monitored for signs of tumor development and toxicity. Eight days after the first day of 
treatment (i.e. 17 days from tumor inoculation), mice were sacrificed and post-mortem was 
performed.  The mean tumor volume was calculated for each treatment group (Figure 7).   
Despite the toxicity of the treatment, the animals in Group 4 (which received AE17-STK + 
GCV) had significantly smaller tumors compared to the mice in the first 3 control groups 
(PBS alone, AE17-STK alone,  or GCV alone) [p = 0.03]. This reduction in tumor volume 
appeared to be reduced slightly in the case of irradiated AE17-STK cells, as there was a 
smaller reduction in tumor volume in Group 5 (which received -irradiated AE17-STK with 
GCV) compared to Group 4 (GCV + AE17-STK), although this reduction was not statistically 
significant (p = 0.56). For Groups 6 and 7 (PA-STK treated groups), the unirradiated PA-STK 
cells + GCV mediated a detectable anti-tumor effect in vivo, whereas the -irradiated PA-STK 
cells and GCV did not (p values = 0.05 and 0.6 respectively), compared to control mice which 
received PBS only. However, the difference between the irradiated PA-STK and unirradiated 
PA-STK cells was statistically significant (p = 0.045). Moreover, both the live and irradiated 
CRL5830-STK human mesothelioma cells in combination with GCV mediated a detectable 
anti-tumor bystander killing effect, compared to control mice which received PBS only, p 
values = 0.05 and 0.06 respectively.    
  
Discussion  
The use of lethally-irradiated allogeneic TK-modified tumor cells could result in the 
development of a ‘generic’ HSV-TK expressing tumor cell line to generate an anti-tumor 
immune response against a number of different tumor types [17,37]. If effective, such a 
strategy could be much more practical, as it could be more easily standardised. In addition it 
could be a less expensive therapeutic option than therapy with autologous modified tumor 
cells [38]. 
The studies described above appear to indicate that irradiation of PA-STK cells abolishes 
their bystander killing ability, because the PA-STK cells are very radiosensitive and die too 
rapidly to enable therapeutic benefit. The radio-sensitivity of the PA-1 and PA-STK cells 
appeared to be much higher than a panel of 10 other cell lines including human and mouse 
mesothelioma cells. The precise mechanism for this difference is unclear but could be a 
result of a deficiency in DNA repair in PA-STK cells.  
In a murine mesothelioma model, Schwarzenberger and his colleagues successfully used PA-
STK ovarian tumor cells to treat peritoneally grown mesothelioma tumor AC29. In this study 
the PA-STK cells were not irradiated [18]. Efficacy of the irradiated TK+ve cells was tested in 
a previous study by Freeman and his colleagues using the TK+ve cells KBALB but not PA-STK 
cells. However, the data presented in this study demonstrate that irradiation of PA-STK cells, 
even at very low doses, makes them lose their capacity to induce an in vitro bystander effect 
as they die very early post-irradiation. 
In this study, irradiated and non-irradiated AE17-STK mouse mesothelioma cells were 
examined for their efficiency in inducing the rejection of allogeneic tumors; AE17-STK cells 
were also compared with a human mesothelioma cell line CRL5830. Tumor regression was 
detected in all animals injected with the non-irradiated allogeneic AE17-STK cells after GCV 
administration whereas in mice treated with the irradiated cells tumor regression was 
detectable in only 60% of the animals. Interestingly, the human mesothelioma CRL5830-STK 
in combination with GCV treatment has indicated significant reduction in tumor mass in 
contrast to PA-STK human cell line.  
The first clinical trial to use a suicide gene (HSV-TK) as a primary therapeutic agent was 
approved in 1991 for the treatment of ovarian carcinoma17. Ovarian cancer cells (PA-1) were 
transfected ex vivo with the gene for HSV-TK and then injected intraperitoneally in nine 
patients with stage III disease. One patient achieved complete remission, whereas others 
showed partial tumor regression. However, data obtained in the present study show that 
these particular cells (PA-STK) were not able to mediate any detectable in vivo bystander 
killing after lethal irradiation; however a detectable but not significant bystander killing was 
found when these cells were not irradiated. The high sensitivity of PA-STK to irradiation 
appeared to be responsible for the complete loss of the bystander effect not only in vivo but 
also in vitro. The non-irradiated PA-STK cells were able to mediate bystander killing in vitro, 
and also to induce a detectable level of in vivo bystander killing. One possible explanation is 
that the PA-STK cells are not very efficient mediators of the direct bystander effect (PA-STK 
IC50 of 20mM GCV, compared to an IC50 of 3mM for AE17-STK or 1mM for CRL5830-TK 
cells). It is possible that the xenogeneic human ovarian PA-STK cells did not very efficiently 
home onto and/or establish gap junctions with the allogeneic murine mesothelioma cells 
[10,39]. However, as already mentioned, Schwarzenberger and colleagues did find that PA-
STK cells can treat AC29 mouse mesothelioma tumors initiated 4 days earlier [18]. However, 
in the present studies in which the PA-STK cells were given on day 9 of tumor inoculation 
there was no evidence of tumor regression after irradiation, although there was clear 
evidence for the induction of tumor elimination by the AE17-STK cells.   
To sum up, the issue of tumor cell sensitivity to -irradiation is critical in cellular therapy, as 
‘optimum’ sensitivity need to be observed carefully. Gene-modified (HSVTK) tumor cells 
which are to be used in cancer patients need to be lethally irradiated so that they will not 
proliferate in the recipient’s body, but still be able to mediate bystander killing. It is 
therefore important to establish whether and when the irradiated gene-modified tumor 
cells would die after irradiation. 
Conclusions  
This study suggests that PA-STK ovarian tumor cells are rather poor mediators of bystander 
killing, and therefore may not be the most efficient cells for future clinical trials. However, 
the in vitro and in vivo results obtained in the present studies suggest that CRL-5830TK 
human mesothelioma cells may be effective inducers of bystander killing for the clinical 
treatment of mesothelioma. Interestingly, CRL-5830TK cells appear to retain their killing 
ability even after lethal irradiation. 
 Although encouraging results are emerging from pre-clinical and some early stage clinical 
studies, further developments are needed. These include: 1- development of relevant 
disease models in higher vertebrates with physiological traits that are adequately 
representative of humans malignancies; 2- development and optimisation of the gene 
delivery systems; 3- further investigation of ways of enhancing the bystander effect; 4- 
modulation of the host immune response to enhance and complement suicide gene 
therapy; 5- further exploration of other therapeutic strategies in combination with suicide 
gene therapy in the light of the observation that certain suicide genes can behave as radio-
sensitising agents [40-42].  
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Figure Legends 
Figure 1. Loss of bystander killing after -irradiation of PA-STK cells (100 Gy) A) 5x105 cells/plate; B) 
2x106 cells/plate. Mixing experiments demonstrate the in vitro bystander effect of the irradiated and 
un-irradiated PA-STK cells. X-axis represents the ratios of PA-STK to PA-1 cells. Y-axis represents % 
colony formation after exposure to 50 M GCV for 5-days. Error bars represent standard error of the 
mean. Representative of three similar experiments. At both cell densities, irradiated PA-STK cells 
were highly significantly less efficient at mediating the bystander effect at a 50:50 ratio than 
unirradiated cells (P = 0.04). Similar data were obtained in three further repeats of this 
experiment.   
Figure 2. In vitro bystander killing induced by -irradiated (100 Gy) mouse mesothelioma AE17-STK 
cells. A- AE17-STK and AE-17 cells (with or without -irradiation) were mixed and cultured in the 
presence of 50 M GCV for 6 days. The total number of cells was 5x104/well of 96-well tissue culture 
plate. Per cent survival was measured using the MTT assay. Each point is the mean of three separate 
measurements and error bars indicating the standard error of the mean are shown. Similar data was 
obtained in three separate experiments. B- In vitro bystander killing induced by the -irradiated 
human mesothelioma cell line CRL-5830TK. CRL5830-STK and CRL5830 cells were mixed in the 
indicated ratios and cultured in the presence of 50 M GCV for 6 days. The total number of cells was 
5x104/well of 96-well tissue culture plate. The fraction of surviving cells was measured using the MTT 
assay. Each point is the mean of three separate measurements and error bars indicate the standard 
error of the mean. Similar data was obtained in three separate experiments. In neither case was 
there a significant difference in efficacy between irradiated and unirradiated cells (P>0.45 at 
all cell ratios).    
 
Figure 3. The effect of -irradiation on OVC-432, PA-1, and PA-STK cells. The cells were either -
irradiated at 100Gy, or not irradiated as controls. The cells were re-plated in 6-well tissue culture 
plates at a density of 5x104 per plate and then were incubated overnight. The plates were then 
visualized and photographed by light microscopy (100X magnification).  
Figure 4. Time course of cell death in -irradiated PA-STK and OVC-432 cells using trypan blue dye 
exclusion. The cells were irradiated at 100Gy and the percentage of trypan blue excluding cells was 
determined at the indicated time points. The counts were performed in triplicate. Error bars 
represent standard error of the mean. Representative of three similar experiments. 
Figure 5.  Apoptosis measured in two human tumor cell lines using annexin V/propidium iodide. Cells 
were analysed with a FACSCalibur flow cytometer: A) HL-60 control cell line either untreated or 
treated with 0.1µM staurosporin for 4 hours. B)  PA-STK cells unirradiated or irradiated at 100Gy. 
The irradiated tumour cells were analysed 10 hours after irradiation. 
Figure 6. Cytospin- histological analysis of irradiated PA-STK ovarian tumor cells. A, control un- 
irradiated cells. B, The PA-STK cells -irradiated at 100Gy, after 18 hours in culture 1x 104 cells were 
centrifuged at 2,400 rpm for 10 minutes. Papanicolaou staining was then performed and cells 
observed at 1000x magnification 
Figure 7. In vivo treatment using allogeneic AE17-STK mouse mesothelioma cells in BALB/c mice. 
BALB/c mice were injected IP with the syngeneic murine mesothelioma cells AB1 (1 x106 cells per 
mouse) on day 0. Nine days later the mice were separated into nine treatment groups as indicated, 
and another healthy group acted as positive control. On day 18, mice were sacrificed and post-
mortem was performed. All tumor nodules were counted and measured using a calliper. Tumor 
volume was calculated for each mouse and the mean tumor volume was calculated for each group. 
The error bars represent standard error of the mean. Irr.  Stands for cells irradiated at 100Gy and 
treated with GCV. See text for detailed experimental conditions. Error bars represent standard error 
of the mean. The difference between unirradiated and irradiated PA-STK cells was statistically 
significant (p = 0.045). Representative of three similar experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
